Contact us

Human clinical trials

We post details of our clinical trials on clinical trial registries, such as the Australian New Zealand Clinical Trials Registry (ANZCTR) at www.anzctr.org.au.

Please note:

• QBiotics is not involved in assessing patients or recommending eligibility for clinical trials – this is something only the independent trial clinicians can undertake.
• If you are interested in participating in one of our clinical trials please speak with your oncologist regarding the trial and its suitability to your specific problem.
• We are unable to discuss any aspects of these trials with potential patients and unfortunately, we cannot respond to emails or phone requests for information about these clinical trials.

We understand how truly difficult this time is for those affected by cancer, as cancer has touched the lives, either personally or through our loved ones, of many of us at QBiotics. Please be assured that we are committed to developing products as quickly as possible, with the goal of effectively and safely providing solutions to challenging medical conditions.

Veterinary clinical trials

Tigilanol tiglate, our lead oncology compound has now been commercialised as a veterinary oncology product, STELFONTA^®*.

STELFONTA* is approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Veterinary Medicines Directorate (VMD), Australian Pesticides and Veterinary Medicine (APVMA) and Swissmedic; making it the first pharmaceutical treatment available for non resectable, non-metastatic mast cell tumours. As STELFONTA is registered as a prescription product, your veterinarian will be able to decide the best treatment for your dog.

We appreciate how distressing a cancer diagnosis for your pet can be, and wish you and your dog the very best during this time.

Warmly, the QBiotics team.

* This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.

STELFONTA^®

Resources for pet owners:
Stelfonta.com/resources

Investors

To request information regarding your Securityholder Reference Number (SRN) please contact QBiotics share registry, MUFG Corporate Markets (AU) Limited (previously Link Market Services Limited) on 1300 554 474 or email support@cm.mpms.mufg.com

To request a change to your mailing or email address you can click the link below to login to your portfolio held with MUFG Corporate Markets (AU) Limited (previously Link Market Services Limited). Alternatively, you can call MUFG Corporate Markets (AU) Limited on 1300 554 474 https://au.investorcentre.mpms.mufg.com/Login/Login